DE69837819T2 - Kondensierte plasmid-liposome komplex zur transfektion - Google Patents

Kondensierte plasmid-liposome komplex zur transfektion Download PDF

Info

Publication number
DE69837819T2
DE69837819T2 DE69837819T DE69837819T DE69837819T2 DE 69837819 T2 DE69837819 T2 DE 69837819T2 DE 69837819 T DE69837819 T DE 69837819T DE 69837819 T DE69837819 T DE 69837819T DE 69837819 T2 DE69837819 T2 DE 69837819T2
Authority
DE
Germany
Prior art keywords
plasmid
liposome
lipid
complexes
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69837819T
Other languages
German (de)
English (en)
Other versions
DE69837819D1 (de
Inventor
Shi Kun Castro Valley HUANG
Edwin Kiyoshi Redwood City OTO
Mohammad Vallejo HASSANIPOUR
Bei Union City JIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of DE69837819D1 publication Critical patent/DE69837819D1/de
Publication of DE69837819T2 publication Critical patent/DE69837819T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being an antibiotic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
DE69837819T 1997-03-28 1998-09-11 Kondensierte plasmid-liposome komplex zur transfektion Expired - Fee Related DE69837819T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/827,236 US5851818A (en) 1996-05-31 1997-03-28 Condensed plasmid-liposome complex for transfection
PCT/US1998/019067 WO2000015825A1 (en) 1997-03-28 1998-09-11 Condensed plasmid-liposome complex for transfection

Publications (2)

Publication Number Publication Date
DE69837819D1 DE69837819D1 (de) 2007-07-05
DE69837819T2 true DE69837819T2 (de) 2008-01-31

Family

ID=26794355

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69837819T Expired - Fee Related DE69837819T2 (de) 1997-03-28 1998-09-11 Kondensierte plasmid-liposome komplex zur transfektion

Country Status (9)

Country Link
US (1) US5851818A (https=)
EP (1) EP1109926B1 (https=)
JP (1) JP2002525270A (https=)
AT (1) ATE362991T1 (https=)
AU (1) AU9568698A (https=)
CA (1) CA2342292A1 (https=)
DE (1) DE69837819T2 (https=)
ES (1) ES2286857T3 (https=)
WO (1) WO2000015825A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US5851818A (en) * 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
US6133026A (en) * 1996-05-31 2000-10-17 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection
ES2392246T3 (es) 1996-11-12 2012-12-07 The Regents Of The University Of California Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
JP4799736B2 (ja) * 1999-02-22 2011-10-26 ジョージタウン・ユニバーシティ 全身性遺伝子送達のための抗体フラグメント標的化イムノリポソーム
US7112337B2 (en) * 1999-04-23 2006-09-26 Alza Corporation Liposome composition for delivery of nucleic acid
CA2383423A1 (en) * 1999-09-17 2001-03-22 Whitehead Institute For Biomedical Research Reverse transfection method
US20020006664A1 (en) * 1999-09-17 2002-01-17 Sabatini David M. Arrayed transfection method and uses related thereto
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
US7429466B2 (en) * 2000-01-24 2008-09-30 Hypromatrix, Inc Methods and arrays for detecting biological molecules
US8143195B2 (en) * 2000-01-24 2012-03-27 Yingjian Wang Arrays for bringing two or more reagents in contact with one or more biological targets and methods for making and using the arrays
WO2003000291A1 (fr) * 2001-06-22 2003-01-03 Techno Network Shikoku Co., Ltd. Vesicules lipidiques, processus de production de vesicules lipidiques et procede d'immobilisation de gene sur ces vesicules lipidiques
US6670129B2 (en) 2001-09-24 2003-12-30 Corning Incorporated Cell transfection apparatus and methods for making and using the cell transfection apparatus
WO2003097805A2 (en) 2002-05-15 2003-11-27 California Pacific Medical Center Delivery of nucleic acid-like compounds
CN100471486C (zh) * 2002-08-12 2009-03-25 戴纳伐克斯技术股份有限公司 免疫调节组合物,其制备方法和使用方法
MXPA05010499A (es) 2003-03-31 2006-05-25 Johnson & Johnson Particulas lipidicas que tienen un revestimiento lipidico asimetrico y metodo de preparacion de las mismas.
JP2007512355A (ja) * 2003-11-21 2007-05-17 アルザ コーポレイション 開裂性のｐｅｇで表面修飾されたリポソーム−ｄｎａ複合体で媒介される遺伝子送達
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
JP4919397B2 (ja) * 2006-06-30 2012-04-18 北海道システム・サイエンス株式会社 核酸導入用組成物
JP4510842B2 (ja) * 2007-03-26 2010-07-28 キヤノン株式会社 ポリヒドロキシアルカノエート被覆リポソーム
CN105451777A (zh) 2013-03-15 2016-03-30 洛马林达大学 自身免疫性疾病的治疗
RU2589280C1 (ru) * 2015-02-09 2016-07-10 Государственное автономное научное учреждение Республики Башкортостан "Центр аграрных исследований" Средство с липосомами, содержащими глутаминовую кислоту и экстракт прополиса, обладающее ноотропной активностью
CN109288794B (zh) * 2018-11-19 2021-02-23 上海交通大学 一种蜂毒素脂质体纳米制剂及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187260A (en) * 1988-09-06 1993-02-16 Sharifa Karali Process for the preparation of a high purity protamine-DNA complex and process for use of same
US5614503A (en) * 1993-11-12 1997-03-25 Aronex Pharmaceuticals, Inc. Amphipathic nucleic acid transporter
US5851818A (en) * 1996-05-31 1998-12-22 Sequus Pharmaceuticals, Inc. Condensed plasmid-liposome complex for transfection

Also Published As

Publication number Publication date
CA2342292A1 (en) 2000-03-23
HK1039633A1 (en) 2002-05-03
ES2286857T3 (es) 2007-12-01
WO2000015825A1 (en) 2000-03-23
EP1109926B1 (en) 2007-05-23
ATE362991T1 (de) 2007-06-15
EP1109926A1 (en) 2001-06-27
US5851818A (en) 1998-12-22
AU9568698A (en) 2000-04-03
DE69837819D1 (de) 2007-07-05
JP2002525270A (ja) 2002-08-13

Similar Documents

Publication Publication Date Title
DE69837819T2 (de) Kondensierte plasmid-liposome komplex zur transfektion
DE69634084T2 (de) Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
Thierry et al. Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA
DE69633669T2 (de) Verfahren zur zelltransfektion mit liposomal-verkapselten nukleinsäuren
DE69820465T2 (de) Liposomen-umschlossene polynukleotidzusammensetzung sowie verfahren
DE69433519T2 (de) Sich selbst zusammensetzendes polynukleotid-abgabesystem, das dendrimer-polykationen enthält
DE69906977T2 (de) In liposomen verkapselte nukleinsäurekomplexe
DE69631149T2 (de) Formulierungen in form von emulsionen zur verabreichung von nukleinsäuren an zellen
DE69826488T2 (de) Stabile partikuläre komplexe lamellarer struktur mit neutraler oder negativer gesamtladung
DE69735382T2 (de) Kationische reagenzien zür transfektion
DE60126801T2 (de) Lipidformulierungen zur zielgerichteten abgabe
DE69505677T2 (de) Liposomales verabreichungssystem für biologisch aktive stoffe
DE69207603T2 (de) Zusammensetzung und verfahren zur behandlung von zystischer fibrose
DE69837274T2 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
DE60036861T2 (de) Verkapselung biologisch aktiver komplexe in liposomen
DE69624801T2 (de) Stabile arzneistoffabgabekomplexe mit lipiden und verfahren zu deren herstellung
AU773515B2 (en) Method for controlling liposome size
US6133026A (en) Condensed plasmid-liposome complex for transfection
DE60014133T2 (de) Lipid zur Verwendung in einer Liposomzusammensetzung zur Abgabe eines Mittels an eine Zelle
JP2004525898A (ja) 両性リポソーム及びその使用
JP2002525270A5 (https=)
DE69802102T2 (de) Formulierung von stabilisierter kationischen transfektionsmittel/nukleinsäuren partikeln
EP3632410A1 (en) Lipidic polynucleotide carriers for cellular delivery
KR100650959B1 (ko) 트랜스펙션용 응축 플라스미드-리포좀 복합체
KR100648025B1 (ko) 트랜스펙션용 응축 플라스미드-리포좀 복합체

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee